Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.7200
-0.0122 (-1.67%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Spero Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Spero Therapeutics stock have an average target of 5.00, which predicts an increase of 594.44% from the current stock price of 0.72.
Analyst Consensus: Buy
* Price targets were last updated on Jan 30, 2025.
Analyst Ratings
The average analyst rating for Spero Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +594.44% | Jan 30, 2025 |
Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $5 | Buy → Hold | Downgrades | $5 | +594.44% | Dec 20, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +594.44% | Dec 2, 2024 |
TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Nov 15, 2024 |
Financial Forecast
Revenue This Year
n/a
from 47.98M
Revenue Next Year
1.33M
EPS This Year
-0.58
from -1.27
EPS Next Year
-0.52
from -0.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 1.4M | 34.1M | ||
Avg | n/a | 1.3M | 33.2M | ||
Low | n/a | 1.3M | 31.9M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 2,473.5% | ||
Avg | - | - | 2,400.0% | ||
Low | - | - | 2,302.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | -0.13 | -0.54 | 0.18 | |
Avg | -0.58 | -0.52 | -0.02 | |
Low | -0.82 | -0.50 | -0.20 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | - | - | - | |
Avg | - | - | - | |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.